Long-term prognostic significance of admission plateletcrit values in patients with non-ST elevation myocardial infarction
Autor: | Emre Akkaya, Serkan Aslan, Mehmet Gül, Huseyin Altug Cakmak, Ozgur Surgit, Ozgur Akgul, Hamdi Pusuroglu, Abdurrahman Eksik, Turab Yakisan, Huseyin Uyarel |
---|---|
Rok vydání: | 2016 |
Předmět: |
Blood Platelets
Male medicine.medical_specialty 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Risk Factors St elevation myocardial infarction Internal medicine Odds Ratio medicine Humans In patient 030212 general & internal medicine Myocardial infarction Mean platelet volume Non-ST Elevated Myocardial Infarction Intensive care medicine Survival analysis Aged Retrospective Studies Heart Failure business.industry Retrospective cohort study Hematology General Medicine Odds ratio Middle Aged Prognosis medicine.disease Survival Analysis Hospitalization Heart failure Multivariate Analysis Cardiology Female business Mean Platelet Volume Biomarkers Follow-Up Studies |
Zdroj: | Blood Coagulation & Fibrinolysis. 27:696-701 |
ISSN: | 0957-5235 |
Popis: | The plateletcrit has been investigated as a new predictor of cardiovascular risk. The objective of our study was to investigate the role of admission plateletcrit in predicting long-term cardiovascular mortality in patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI). We enrolled 296 patients with NSTEMI (mean age 59.2 ± 11.8 years; 228 men, 68 women) in this study. The study population was divided into tertiles on the basis of admission plateletcrit values. A high plateletcrit (n = 98) was defined as a value in the upper third tertile (plateletcrit0.23), and a low plateletcrit (n = 198) was defined as any value in the lower two tertiles (plateletcrit ≤0.23). The median follow-up time was 38 months. In multivariate analyses, a significant association was noted between high plateletcrit values and the adjusted risk of long-term mortality (odds ratio = 12.15, 95% confidence interval = 1.78-82.77; P 0.001). In the Kaplan-Meier survival analysis, the long-term mortality rate was 20.4% in the high plateletcrit group versus 4.5% in the low plateletcrit group (P 0.001). Long-term major advanced cardiac events (MACE), hospitalization for heart failure and reinfarction were significantly higher in patients with high plateletcrit. Admission plateletcrit is a strong and independent predictor of long-term cardiovascular mortality in patients with NSTEMI. |
Databáze: | OpenAIRE |
Externí odkaz: |